ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
ALX Oncology Holdings (Nasdaq: ALXO), a clinical-stage biotechnology company focused on developing cancer therapies, has announced it will release its first quarter 2025 financial results on Thursday, May 8th, 2025, before the market opens. The company has specified that it will not hold a conference call to discuss the results.
ALX Oncology Holdings (Nasdaq: ALXO), una società biotecnologica in fase clinica specializzata nello sviluppo di terapie oncologiche, ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 giovedì 8 maggio 2025, prima dell'apertura del mercato. La società ha specificato che non terrà una conference call per discutere i risultati.
ALX Oncology Holdings (Nasdaq: ALXO), una empresa biotecnológica en etapa clínica enfocada en el desarrollo de terapias contra el cáncer, ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el jueves 8 de mayo de 2025, antes de la apertura del mercado. La compañía ha especificado que no realizará una llamada conferencia para discutir los resultados.
ALX Oncology Holdings (나스닥: ALXO)는 암 치료제 개발에 중점을 둔 임상 단계 생명공학 회사로, 2025년 1분기 재무 결과를 2025년 5월 8일 목요일 시장 개장 전에 발표할 예정이라고 밝혔습니다. 회사는 결과에 대해 논의하는 컨퍼런스 콜을 진행하지 않을 것이라고 명확히 했습니다.
ALX Oncology Holdings (Nasdaq : ALXO), une société biotechnologique en phase clinique spécialisée dans le développement de thérapies contre le cancer, a annoncé qu'elle publierait ses résultats financiers du premier trimestre 2025 le jeudi 8 mai 2025, avant l'ouverture des marchés. La société a précisé qu'elle ne tiendrait pas de conférence téléphonique pour discuter des résultats.
ALX Oncology Holdings (Nasdaq: ALXO), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Krebstherapien spezialisiert hat, hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Donnerstag, den 8. Mai 2025, vor Börsenbeginn zu veröffentlichen. Das Unternehmen hat angegeben, dass keine Telefonkonferenz zur Besprechung der Ergebnisse stattfinden wird.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open.
The company will not be hosting a teleconference in conjunction with its financial results press release.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577
FAQ
When will ALXO release its Q1 2025 earnings?
Will ALX Oncology host a conference call for Q1 2025 earnings?
What type of company is ALXO?
What is ALX Oncology's stock symbol?
